



References

- 1. Food and Drugs Act
- 2. Food and Drug Regulations: Part C, Division 5, Drugs for Clinical Trials Involving Human Subjects
- 3. Natural Health Products Regulations: Part 4, Clinical Trials Involving Human Subjects
- 4. Medical Devices Regulations: Part 3, Medical Devices for Investigational Testing Involving Human Subjects
- 5. Personal Information Protection and Electronic Documents Act
- 6. United States Code of Federal Regulations: 21 CFR 50, 56, 312, 812 and 45 CFR 46
- ICH GCP International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – ICH Harmonised Tripartite Guideline – Guidelines for Good Clinical Practice E6(R2)
- 8. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, TCPS2 2018
- 9. World Medical Association (WMA). Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
- 10.Guidance Document: Part C, Division 5 of the Food and Drug Regulations "Drugs for Clinical Trials Involving Human Subjects" (Gui-0100) –(August 20, 2019)
- 11.Canadian Association of Research Ethics Boards. Guidance on Reporting of Unanticipated Problems Including Adverse Events to Research Ethics Boards in Canada (July 2010)
- 12.U.S. Department of Health and Human Services, Office for Human Research Protections, and FDA Institutional Review Board Written Procedures Guidance for Institutions and IRBs (May 2018)
- 13.U.S. Department of Health and Human Services, Office for Human Research Protections. Guidance on Reporting Incidents to OHRP (May 2011).
- 14.U.S. Department of Health and Human Services, Office for Human Research Protections. Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events (January 2007)
- 15.U.S. Department of Health and Human Services, Office for Human Research Protections. Guidance on IRB Continuing Review of Research (November 2010)
- 16.U.S. Department of Health and Human Services, Office for Human Research Protections. Guidance on the Use of Expedited Review Procedures (August 2003)
- 17.U.S. Department of Health and Human Services, Office for Protection from Research Risks. Memorandum re: IRB Meetings Convened via Telephone Conference Call (March 2000)
- 18.U.S. Department of Health and Human Services, Office for Protection from Research Risks and Food and Drug Administration. Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure. Federal Registrar: November 9, 1998 (Volume 63, Number 216)





References

- 19.U.S. Department of Health and Human Services, Food and Drug Administration. A Guide to Informed Consent Information Sheet; Guidance for Institutional Review Boards and Clinical Investigators
- 20.U.S. Department of Health and Human Services, Food and Drug Administration. Comparison of FDA and HHS Human Subject Protection Regulations
- 21.U.S. Department of Health and Human Services, Food and Drug Administration. Sponsor-Investigator-IRB Interrelationship – Information Sheet; Guidance for Institutional Review Boards and Clinical Investigators
- 22.U.S. Department of Health and Human Services, Food and Drug Administration. Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors; FDA Institutional Review Board Inspections (April 2019)
- 23.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research (April 2013)
- 24.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry; Investigator Responsibilities – Protecting the Rights, Safety, and Welfare of Study Subjects (October 2009)
- 25.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Clinical Investigators, Sponsors, and IRBs; Adverse Event Reporting to IRBs Improving Human Subject Protection (January 2009)
- 26.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for IBRs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed (August 2013)
- 27.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Continuing Review after Clinical Investigation Approval (February 2012)
- 28.U.S. Department of Health and Human Services, Food and Drug Administration. Institutional Review Boards Frequently Asked Questions – Information Sheet; Information Sheet – Guidance for Institutional Review Boards and Clinical Investigators
- 29.U.S. Department of Health and Human Services. Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subjects Protection (May 2004)
- 30.U.S. Department of Health and Human Services, National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research (November 2017)
- 31.U.S. Department of Health and Human Services, National Institutes of Health. Guidance on NIH Office of Extramural Research (OER) on-line tutorial Protecting Human Research Participants (PHRP) (February 2008)





References

- 32.U.S. Department of Health and Human Services, National Institutes of Health. Frequently Asked Questions; Human Subjects Research Requirement for Education
- 33.Canadian Institutes for Health Research. Best Practices for Protecting Privacy in Health Research (September 2005)